<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066062</url>
  </required_header>
  <id_info>
    <org_study_id>Invictus Registry</org_study_id>
    <nct_id>NCT04066062</nct_id>
  </id_info>
  <brief_title>Multicentre Registry of CCTA, IVUS and OCT</brief_title>
  <official_title>Registry of Coronary Computed Tomography Angiography Intravenous Ultrasound and Optical Coherence Tomography to Compare Invasive/Non-invasive Imaging Modalities for Determination of Severity Volume and Type of Coronary Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleerly, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toho University – Omori Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cleerly, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Invictus Registry will compare the diagnostic performance of coronary computed tomography
      angiography (CCTA) versus intravascular imaging by intravenous ultrasound (IVUS) or optical
      coherence tomography (OCT) for the measurement of minimum lumen area, the identification of
      stenosis severity, burden, morphology and vulnerability of coronary atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Significance:

      Coronary computed tomographic angiography (CCTA) is a robust non-invasive modality to
      evaluate the presence, extent and severity of Coronary Artery Disease (CAD). For a plaque
      assessment, previous studies demonstrated that CCTA provides a high correlation with
      intravascular imaging by intravenous ultrasound (IVUS) in assessing coronary plaque
      characteristics stenosis severity and volume. High risk (vulnerable) plaque characteristics
      (positive remodeling, low attenuation plaque, spotty calcifications) are recognized to be
      more prone to rupture with increased rates of short-term cardiovascular disease events.
      Although several studies similarly demonstrated the good concordance between CCTA and IVUS or
      optical coherence tomography (OCT) in assessing high risk plaque features, patient numbers in
      these prior studies were limited to fully understand the effect of CCTA for the assessment of
      coronary atherosclerotic plaque features.

      The Research is a multi-center, registry enrolling patients with single/multi vessel
      atherosclerotic coronary artery disease. The study will be conducted in up to 15 Medical
      Centers in Japan. In each patient, a CCTA, IVUS), and/ or OCT will be performed, to provide a
      total of 1,300 vessels from 1,000 patients. Thus, the full cohort (Prospective plus
      Retrospective patients) will provide a total of 2,000 vessels as basis for a diagnostic
      performance comparison between CCTA and IVUS or OCT. Accrual is expected to take 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>To compare the diagnostic performance of CCTA versus IVUS or OCT for the measurement of minimum lumen area.</measure>
    <time_frame>June 2019- June 2021</time_frame>
    <description>Patients will undergo invasive coronary angiography with IVUS/OCT for the measurement of minimum lumen area, the identification of stenosis severity, burden, morphology and vulnerability of coronary atherosclerosis.
The co-registration of IVUS/OCT images with CCTA segmented images will be implemented in the following three stages by locating the corresponding anatomical landmarks/fiduciary points (coronary ostia, side-branches, calcified plaques, and/or overlapping veins) and matching the corresponding coronary segments in all the imaging modalities</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Retrospective</arm_group_label>
    <description>A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
    <description>A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with single/multi vessel atherosclerotic coronary artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent, inclusive of release of medical information, and Health
             Insurance Portability and Accountability Act (HIPAA) documentation

          -  Age 18 years or older

          -  Known or suspected Coronary Artery Disease and subsequently indicated for coronary
             artery angiography

        Exclusion Criteria:

          -  Individuals unable to provide informed consent

          -  Acute ST elevation myocardial infarction

          -  Pregnant woman

          -  Angiographically visible thrombus at the site of the lesion interrogated by IVUS or
             OCT

          -  Patients with lesions required balloon angioplasty before OCT and/or IVUS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rine Nakanishi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University – Omori Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Stern, MBA, MS</last_name>
    <phone>5164565531</phone>
    <phone_ext>5164565531</phone_ext>
    <email>jamie.stern@cleerlyhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Min, MD</last_name>
    <phone>6463624255</phone>
    <email>james.min@cleerlymed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ehime University</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Kurata, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiro Kitagawa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yotsuba Circulation Clinic</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitsunori Abe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama Red Cross Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhiro Osawa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toho University Omori Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>143-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rine Nakanishi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ryo Okubo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edogawa Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideyuki Sato, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroki Ikenaga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakakibara Heart Institute</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuo Iguchi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mike Saji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokai University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigemitsu Tanaka, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

